Israel - English - Ministry of Health

sanofi israel ltd - zolpidem tartrate - film coated tablets - zolpidem tartrate 10 mg - zolpidem - zolpidem - indications are limited to treatment of severe sleep disorders in the following cases: - occasional insomnia - transient insomnia.

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin lispro - diabetes mellitus - drugs used in diabetes - for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. insulin lispro sanofi is also indicated for the initial stabilisation of diabetes mellitus.

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - diabetes mellitus - drugs used in diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dupilumab, quantity: 175 mg/ml - injection, solution - excipient ingredients: arginine hydrochloride; histidine; polysorbate 80; sodium acetate; glacial acetic acid; sucrose; water for injections - dupixent is indicated for the following type 2 inflammatory diseases:,atopic dermatitis,adults and adolescents,dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. dupixent is not intended for episodic use.,children 6 months to 11 years of age,dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. dupixent is not intended for episodic use.,asthma,dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated feno) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see section 5.1 pharmacodynamic properties ? clinical trials).,chronic rhinosinusitis with nasal polyposis (crswnp),dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (crswnp).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dupilumab, quantity: 150 mg/ml - injection, solution - excipient ingredients: arginine hydrochloride; water for injections; polysorbate 80; sucrose; histidine; glacial acetic acid; sodium acetate trihydrate - dupixent is indicated for the following type 2 inflammatory diseases:,atopic dermatitis,adults and adolescents,dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. dupixent is not intended for episodic use.,children 6 to 11 years of age,dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. dupixent is not intended for episodic use.,prurigo nodularis,dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (pn) in adults who are candidates for systemic therapy.,asthma,dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated feno) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see section 5.1 pharmacodynamic properties ? clinical trials).,chronic rhinosinusitis with nasal polyposis (crswnp),dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (crswnp). dupixent is indicated for the following type 2 inflammatory diseases:,atopic dermatitis,adults and adolescents,dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. dupixent is not intended for episodic use.,children 6 months to 11 years of age,dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. dupixent is not intended for episodic use.,asthma,dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated feno) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see section 5.1 pharmacodynamic properties ? clinical trials).,chronic rhinosinusitis with nasal polyposis (crswnp),dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (crswnp).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - cemiplimab, quantity: 350 mg - injection, intravenous infusion - excipient ingredients: sucrose; histidine; histidine hydrochloride monohydrate; water for injections; proline; polysorbate 80 - cutaneous squamous cell carcinoma,libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. non-small cell lung cancer,libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 tumour proportion score (tps) greater than and equal to 50% as determined by a validated test, with no egfr, alk or ros1 aberrations, who have:,? locally advanced nsclc and who are not candidates for surgical resection or definitive chemoradiation, or ? metastatic nsclc.,libtayo in combination with platinum-based chemotherapy is indicated for the first-line treatment of patients with nsclc whose tumours have no egfr, alk or ros1 aberrations and is:,? locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or,? metastatic. basal cell carcinoma,libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (bcc) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi - aventis groupe - insulina glargina - insulina glargina....100 u/1ml / lixisenatida....33 mcgml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis groupe - lixisenatide - solution for injection - 10 µg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis groupe - lixisenatide - solution for injection - 20 µg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis groupe - lixisenatide - solution for injection - 20 µg